Biogen, Skyhawk enter strategic collaboration for neurological disease treatment Biogen and Therapeutics announced a strategic collaboration in which the companies will leverage Skyhawk’s SkySTAR technology platform with the goal of discovering innovative small molecule treatments for patients with neurological diseases. Biogen will have the option to license therapies resulting from the collaboration and will be responsible for their development and potential commercialization. The agreement grants Biogen an exclusive license to worldwide intellectual property rights on research-stage therapeutic candidates for the treatment of multiple sclerosis, spinal muscular atrophy and additional neurological disorders. As part of the agreement, Skyhawk received an upfront payment of $74M from Biogen and may receive potential future milestone payments and royalties. A portion of the upfront payment will be allocated to future research services, with the remainder expensed in Q1 as research and development.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.